Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%
Genocea Biosciences Inc (NASDAQ:GNCA) was the target of a large increase in short interest in January. As of January 31st, there was short interest totalling 2,870,612 shares, an increase of 73.9% from the January 12th total of 1,651,170 shares. Based on an average daily trading volume, of 1,916,972 shares, the short-interest ratio is presently 1.5 days. Approximately 6.7% of the shares of the stock are short sold.
Several institutional investors and hedge funds have recently made changes to their positions in GNCA. Schwab Charles Investment Management Inc. bought a new stake in shares of Genocea Biosciences in the 2nd quarter worth approximately $257,000. Rhumbline Advisers bought a new stake in shares of Genocea Biosciences in the 2nd quarter worth approximately $157,000. Bank of New York Mellon Corp lifted its holdings in shares of Genocea Biosciences by 594.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 84,119 shares of the biotechnology company’s stock worth $439,000 after acquiring an additional 72,008 shares during the last quarter. Teachers Advisors LLC bought a new stake in shares of Genocea Biosciences in the 2nd quarter worth approximately $268,000. Finally, TIAA CREF Investment Management LLC bought a new stake in shares of Genocea Biosciences in the 2nd quarter worth approximately $404,000. Hedge funds and other institutional investors own 12.02% of the company’s stock.
Shares of Genocea Biosciences (NASDAQ:GNCA) traded down $0.05 on Friday, hitting $0.93. 1,765,376 shares of the stock were exchanged, compared to its average volume of 1,300,435. The company has a market cap of $76.32, a price-to-earnings ratio of -0.43 and a beta of 1.55. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 2.51. Genocea Biosciences has a 1 year low of $0.79 and a 1 year high of $7.29.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/short-interest-in-genocea-biosciences-inc-gnca-grows-by-73-9/1855805.html.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.